<DOC>
	<DOCNO>NCT00979407</DOCNO>
	<brief_summary>The primary purpose study assess equivalence immune response elicit two GSK Biologicals ' adjuvanted influenza investigational vaccine ( GSK2340272A GSK2340274A ) adult age 18 60 year . The second purpose study evaluate safety reactogenicity two vaccine .</brief_summary>
	<brief_title>Study Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines Adults ( H1N1 )</brief_title>
	<detailed_description>This Protocol Posting update follow Protocol Amendment 4 , July 2010 , lead removal one secondary outcome measure .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female age 18 60 year inclusive , time first vaccination . Subjects investigator believe comply requirement protocol . Written inform consent obtain subject . Satisfactory baseline medical assessment history physical examination . Access consistent mean telephone contact , may either home workplace , land line mobile , NOT pay phone multipleuser device Females nonchildbearing potential may enrol study . Female childbearing potential may enrol study , : practice adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine plan use study period . Presence evidence substance abuse neurological psychiatric diagnosis , although stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Presence axillary temperature &gt; = 37.5°C ( 99.5°F ) , acute symptom great `` mild '' severity schedule date first vaccination . NOTE : The subject may vaccinate later date , provide symptom resolve , vaccination occurs within window specify protocol , eligibility criterion continue satisfy . Clinically virologically confirm influenza infection within 6 month precede study start . Diagnosed cancer , treatment cancer , within 3 year . Any confirm suspected immunosuppressive immunodeficient condition include history human immunodeficiency virus ( HIV ) infection . Clinically virologically confirm influenza infection within 6 month precede study start . Chronic administration immunosuppressant immune modify drug within 6 month study enrolment plan administration study period . Receipt immunoglobulins and/or blood product within 3 month study enrolment plan administration product study period . Any significant disorder coagulation treatment warfarin derivative heparin . An acute evolve neurological disorder history GuillainBarré syndrome . Administration vaccine within 30 day vaccination . Any known suspected allergy constituent influenza vaccine ; history anaphylactictype reaction constituent influenza vaccine ; history severe adverse reaction previous influenza vaccine . Pregnant lactate female Female planning become pregnant planning discontinue contraceptive precaution . Any condition , opinion investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>influenza infection</keyword>
	<keyword>GSK Biologicals ' influenza vaccine GSK2340272A GSK2340274A</keyword>
</DOC>